Table 3. Risk of end-stage liver disease and HCC.
| End-stage liver disease |
HCC |
|||||||
|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariable model |
Univariate |
Multivariable model |
|||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Male sex | 6.575 (0.881–49.053) | 0.066 | 5.298 (0.692–40.526) | 0.108 | 30.721 (0.152–6,191.832) | 0.206 | ||
| Age | 1.060 (1.024–1.097) | 0.001 | 1.039 (0.997–1.083) | 0.067 | 1.062 (1.018–1.109) | 0.005 | 1.033 (0.982–1.088) | 0.211 |
| Treatment-naïve | 1.094 (0.400–2.994) | 0.861 | 1.301 (0.407–4.161) | 0.658 | ||||
| Treatment | 1.026 (0.466–2.262) | 0.949 | 1.222 (0.459–3.255) | 0.688 | ||||
| Baseline ALT, U/L | 0.527 (0.191–1.453) | 0.216 | 0.996 (0.988–1.004) | 0.314 | ||||
| Baseline HBV DNA, log10IU/L | 1.139 (0.472–2.749) | 0.773 | 0.915 (0.317–2.639) | 0.869 | ||||
| PLT, 109/L | 0.982 (0.972–0.991) | 0.000 | 0.991 (0.980–1.003) | 0.146 | 0.982 (0.971–0.994) | 0.003 | 0.996 (0.982–1.010) | 0.569 |
| HBeAg-positive | 1.622 (0.682–3.854) | 0.274 | 2.119 (0.709–6.332) | 0.179 | ||||
| LLV | 6.695 (2.225–20.141) | 0.001 | 6.280 (2.081–18.951) | 0.001 | 4.847 (1.323–17.756) | 0.017 | 5.108 (1.392–18.737) | 0.014 |
| Cirrhosis | 13.271 (3.902, 45.137) | 0.000 | 6.378 (1.623–25.074) | 0.008 | 27.168 (3.546–208.166) | 0.001 | 18.316 (2.005–167.307) | 0.010 |
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; HBV, hepatitis B virus; PLT, platelets; HBeAg, hepatitis B e antigen; LLV, low-level viremia.